Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms

Table 1 Demographic background and clinical characteristics of the participants

	Placebo-administered group (N = 40)		Oxytocin-administered group (N = 43)		Oxytocin versus placebo group	Time-course change group (N = 20)		Time-course change versus placebo group
	Mean	SD	Mean	SD	p value^c	Mean	SD	p value^c
Age (range)	26.4 (18–46)	6.9	28.2 (18–48)	7.4	0.26	30.9 (22–47)	6.6	0.02
Height, cm	172.2	5.7	170.5	6.4	0.21	170.5	6.1	0.30
Body weight, kg	66.7	11.5	67.3	11.5	0.80	69.5	11.2	0.37
SES^a	2.8	1.2	3.2	1.0	0.08	3.3	1.1	0.12
Parental SES^a	2.2	0.6	2.2	0.6	0.66	2.1	0.6	0.75
Handedness: Right/left	37/3		41/2			20/0
IQ^b
Full IQ	110.3	14.1	105.2	13.7	0.10	106.4	14.6	0.31
Verbal IQ	116.5	14.3	110.7	13.2	0.06	110.8	13.4	0.14
Performance IQ	100.2	14.7	96.5	15.4	0.27	98.1	16.3	0.61
ADIR
Social	21.9	5.2	21.2	5.0	0.57	21.7	4.4	0.91
Communication	16.3	3.4	15.6	3.9	0.36	15.8	3.6	0.56
Repetitive	5.9	2.3	5.3	2.6	0.36	5.3	2.6	0.41

SES, socioeconomic status; IQ, intelligence quotient; SD, standard deviation; ADIR, Autism Diagnostic Interview—Revised
^aSES assessed using the Hollingshead scale. Higher scores indicate lower status
^bIntelligence quotients were measured using the Wechsler Adult Intelligence Scale
^cp values were calculated using the independent t-test

ISSN: 2040-2392